0000950170-23-039165.txt : 20230807
0000950170-23-039165.hdr.sgml : 20230807
20230807171149
ACCESSION NUMBER: 0000950170-23-039165
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230804
FILED AS OF DATE: 20230807
DATE AS OF CHANGE: 20230807
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burgess Paul D.
CENTRAL INDEX KEY: 0001744627
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39311
FILM NUMBER: 231148465
MAIL ADDRESS:
STREET 1: C/O TRANSLATE BIO, INC.
STREET 2: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001805387
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 844-304-2048
MAIL ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II
DATE OF NAME CHANGE: 20200303
4
1
ownership.xml
4
X0508
4
2023-08-04
0001805387
Cerevel Therapeutics Holdings, Inc.
CERE
0001744627
Burgess Paul D.
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE
MA
02141
false
true
false
false
See Remarks
false
Common Stock
2023-08-04
4
P
false
21880
22.9339
A
21880
D
The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.85 - $22.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Chief Business Development and Strategic Operations Officer
/s/ Mark Bodenrader, as Attorney-in-Fact
2023-08-07